Radiosensitising Nanoparticles as Novel Cancer Therapeutics — Pipe Dream or Realistic Prospect? by Coulter, J. A. et al.
Radiosensitising Nanoparticles as Novel Cancer Therapeutics —
Pipe Dream or Realistic Prospect?
Coulter, J. A., Hyland, W. B., Nicol, J., & Currell, F. J. (2013). Radiosensitising Nanoparticles as Novel Cancer
Therapeutics — Pipe Dream or Realistic Prospect? Clinical Oncology, 25(10), 593-603. DOI:
10.1016/j.clon.2013.06.011
Published in:
Clinical Oncology
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2013 Elsevier.
Licensed under the Creative Commons Attribution -NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:15. Feb. 2017
        
Radiosensitising nanoparticles as novel cancer therapeutics - Pipe 
dream or realistic prospect? 
 
Authors: Jonathan A Coulter1, Wendy B Hyland1,4, James Nicol1, Fred J 
Currell2 
 
Affiliation: 1School of Pharmacy, McClay Research Centre, Queen’s 
University Belfast. 2School of Mathematics and Physics, Queens University 
Belfast. 4Belfast Health and Social Care Trust. 
 
Corresponding author:  
Dr. Jonathan A Coulter 
School of Pharmacy 
Queen’s University Belfast 
97 Lisburn Road, Belfast 
BT9 7BL 
UK Phone: +44(0) 28 90972253; Fax +44(0) 28 90247794 
Email: j.coulter@qub.ac.uk 
 
Word count: 4194 
 Abstract 
The field of high atomic number nanoparticle radiosensitising agents is 
reviewed. After a brief discussion of the new mode of physicochemical 
action implied by irradiation of high atomic number nanoparticles 
embedded in biological systems, a series of exemplars are discussed. 
Silver-, gallium-and gold-based nanoparticles are discussed in order of 
increasing atomic number with functionalization strategies being 
outlined. In-vitro and in-vivo evidence for radioenhancement and the 
mechanisms attributed to the increased biological effect are discussed. 
 
Introduction  
An interdisciplinary approach to the development of future therapeutics 
has helped fuel the nanoscale revolution of the past decade. This has led 
to the production of a multiple of nanoparticle preparations for the 
treatment of a variety of pathological conditions ranging from novel 
scaffolds for tissue engineering, to new HIV therapeutics and perhaps 
most commonly for the development of new anti-cancer agents (1-4). This 
review specifically details various nanoparticle preparations that have 
been created to augment the efficacy of current radiotherapy treatment 
plans.  
By far the most common radiosensitising approach is to exploit the 
increased photon absorption of high atomic number (Z) materials at 
kilovoltage (kVp) photon energies (5). Adopting this approach, 
therapeutic nanoparticles have been produced using silver (Z=47), 
gadolinium (Z=64) and most extensively gold (Z=79). In addition to the 
high atomic number of these materials, the unique physicochemical 
properties of these nanomaterials permit relatively simplistic 
functionalisation through the binding of amine and thiol subgroups (6). 
Furthermore, increasingly complex multifunctionalisation strategies have 
resulted in new terminology such as theranostics, where a particle is 
designed for both therapeutic and diagnostic purposes (7, 8).  
Physicochemical mode of action 
In contrast to the low-atomic number species found predominantly in 
living systems, the presence of the high-Z species interacting with highly 
ionising radiation implies a new physicochemical mode of action. Due to 
the photoelectric effect, these high atomic number species can undergo 
inner-shell ionization – where one of the deeply bound electrons is 
removed – with high efficiency. The result is a highly unstable atomic 
system that stabilizes by emission of lower energy photons (fluorescence) 
and electrons (Auger emission). Several Auger emissions can occur 
effectively simultaneously from a single inner shell ionization in a process 
called an Auger cascade. The electrons produced by this Auger cascade 
typically have energies of a few keV or less and hence they have 
penetrations of typically 10 to 100 nm (9). As a result, these electrons 
deposit their energy very locally. This highly localized deposition of energy 
is akin to that found in ion therapy and indeed the biological effect has 
been well described using the local effect model first developed to relate 
ion-induced radiation track structure to biological effect (10, 11). This 
highly localized deposition of energy is one of the attractive features of 
nanoparticles clinically – if appropriately localized, they offer the promise 
of performance usually associated only with heavy ion facilities but using 
conventional clinical linacs. However, a full description of the mode of 
action following from the localized energy deposition brought about 
through the Auger cascade is still not available. For example, the energy 
dependence for DNA damage by gold nanoparticles in the photon energy 
range (20 – 80 keV) shows an unexplained double maximum (12). This is 
significant because this energy range is the range over which 
photoelectric interactions with gold nanoparticles (e.g. from shower 
particles) are most likely. This unexplained energy dependence in even 
such a simple system shows the difficulty in connecting this collective 
physical mode of action, via physicochemical processes to biological 
effects. The physical basis of radiosensitization and the resultant 
biological mechanisms have been reviewed elsewhere, for the specific 
case of gold nanoparticles  (13). 
 
Silver Nanoparticles (Z=47) 
Zhao et al (2012) developed a multifunctional magnetic iron/silver 
nanocomposite particle functionalised, with Cetuximab, a monoclonal 
antibody designed to target the epidermal growth factor receptor (EGFR) 
(14). This is an attractive target as upregulation of EGFR is commonly 
observed in many cancers including nasopharyngeal carcinomas and is 
strongly associated with tumour metastasis, recurrence and poor overall 
survival  (15, 16). The Fe(3)O(4)/Ag–cetuximab nanoparticle evoked dose 
dependent cytotoxicity with an IC50 concentration of 350 ± 3.14 μg/L. 
However, when used in combination with radiation at 30 μg/L (~10% of 
the IC50 concentration) significant radiosensitisation was achieved 
producing an impressive dose enhancement factor (DEF) of 2.26. In 
addition, to high Z radiosensitation caused by the Ag nanoparticles, 
additional functionality was conferred by the conjugation of Cetuximab 
resulting in the attenuation of EGFR by approximately 50%  (14). This 
reduction is particularly relevant as EGFR signalling through downstream 
pathways such as Ras-mitogen-activated protein kinase (MAPK), 
phosphatidyl inositol 3-kinase (PI3K)-Akt and Jak-STAT have been 
associated with solid tumour radio-resistance  (17, 18). An earlier study 
investigating silver nanoparticles as sensitisers for the treatment of 
radioresistant glioblastoma tumors reported variable efficacy dependent 
upon nanoparticle size and concentration  (19). The extent of the 
sensitising capability was further enhanced using higher concentrations 
of the nanoparticles, while maximizing the surface area to volume ratio 
by opting for smaller sized particles. In this instance the authors propose 
that the mode of sensitisation is due to the release of Ag+ cations, which 
subsequently capture free electrons generating an oxidative agent, which 
further reduced ATP production and increased the production of 
intercellular reactive oxygen species (ROS)  (20). In addition to enhancing 
the generation of potentially damaging radicals, Ag nanoparticles have 
also been shown to negatively regulate the activity of DNA dependent 
protein kinase (DNA-PK), a key enzyme involved in DNA damage repair via 
Non-homologous End Joining (NHEJ) (21). This finding is particularly 
relevant, as the primary mode of radiation-induced cytotoxicity is the 
generation of potentially lethal double strand breaks (DSB), therefore 
novel therapeutics that augment the radiation induced damage profile 
while inhibiting the repair process have attracted much attention  (22, 
23).  
 
Gadolinium Nanoparticles (Z=64) 
Other high Z materials such as Gadolinium (Gd) have been investigated on 
the nanoscale as potential radiosensitising agents. Le Duc et al have 
developed a 2 nm gadolinium nanoparticle (GdNp) as a positive contrast 
agent to enhance magnetic resonance imaging and as a novel 
radiosensitiser  (24). A rat intracerebral 9 L gilosarcoma (9LGS) model was 
chosen to demonstrate the theranostic properties of this nanoparticle 
preparation. The authors describe both preferential accumulation within 
the tumors, attributed to the enhanced permeability and retention effect 
(EPR) caused by the tortuous and leaky tumour vasculature and an 
increased radiosensitising capacity  (24-26). This effect was neatly 
demonstrated by the difference in clearance rates between the two 
hemispheres of the brain. In the normal left hemisphere of the rat brain 
the GdNps signal increased for up to 5 min, after which point the 
intracerebral concentration rapidly decreased by approximately 53 %, 20 
min post administration of the nanoparticles. However, in the right 
hemisphere and in particular within the 9LGS tumour, GdNps were 
retained and cleared much slower with 88% of the maximal GdNps 
retained 20 min post administration (24) Figure 1. On this occasion image 
guided microbeam (~25-100 μm) radiation therapy, designed to spare 
normal brain tissue was administered, using the positive MRI signal 
conferred by the GdNps, as a treatment delivery guide. Due to the 
extremely aggressive and invasive nature of gliosarcoma tumours, the 
median survival time (MeST) for untreated animals was 19 days. This was 
significantly improved upon with the administration of microbeam 
radiation therapy extending the MeST to 47 days, an increase in survival 
time by 147%. However, the radiosensitising effect conferred by the 
GdNps profoundly augmented the therapeutic benefit of radiotherapy, 
extending the MeST to 90 days, an increase in overall survival time of 
373% compared to untreated animals and 191% over radiation therapy 
alone  (24). This could have a significant clinical impact, as the long-term 
prognosis for many patients developing glioblastoma tumours is 
particularly bleak, with a median survival rate of 1-year post diagnosis  
(27).  
Gadolinium-chemotherapeutic conjugates have also been used with 
radiotherapy, a number of which have entered clinical trials. One of the 
most widely used is Motexafin Gadolinium ((MGd) – trade name-Xcytrin), 
a redox-active porphyrin-like texaphyrin licensed by the FDA for the 
treatment of non-small cell lung cancer with secondary brain metastases  
(28). With this novel therapeutic, radiosensitisation is though to be less 
modulated by the high atomic number of MGd, but more directly 
associated with an imbalance in the radical scavenging capability of the 
target cells. MGd promotes both the generation of ROS through the 
oxidation of various intracellular metabolites such as ascorbate, NADPH 
and glutathione. This continual cycle of ROS production effectively 
depletes the cells of the reducing agents required to repair cytotoxic 
damage, thus permitting the accumulation of potentially lethal radiation 
induced DNA double strand breaks  (29, 30). Furthermore, in addition to 
elevating the production of intracellular ROS, MGd also negatively 
regulates the ability of the cell to eliminate ROS. This is primarily 
modulated through the impaired activity of thioredoxin reductase (TrxR1) 
an important enzyme of the antioxidant system, thus permitting the 
accumulation of potent reactive oxygen intermediates such as superoxide 
and hydrogen peroxide  (31, 32). Finally, MGd has also been shown to 
inhibit the DNA synthesis/repair processes by suppressing the activity of 
the enzyme ribonucleotide reductase (RAR), the primary role of which is 
to maintain the reserves of dNTPs required for efficient DNA repair and 
replication. Detailed confocal microscopy studies have identified co-
localisation between MGd and the R1 subunit of the RAR enzyme, which 
is associated with impaired S-phase DNA synthesis. This multimodal 
action has produced impressive anti-cancer effects in both pre-clinical 
models and in the clinical setting  (31, 33). Clinically, MGd has primarily 
been used as a treatment for brain tumours with a phase I study in 
children to determine the maximum tolerated dose. In total, 44 children 
received increasing doses of MGd ranging from 1.7 mg/kg to 9.2 mg/kg 
per day prior to radiation therapy for up to 6 weeks. The maximum 
tolerated dose within the approved ethical parameters of the study was 
4.4 mg/kg with the primary reported toxicity being grade 3-4 
hypertension. This relatively low toxicity profile and the pre-clinical 
studies supporting clinical efficacy have ensured progression to phase II 
clinical trials  (34). 
 
Gold nanoparticles (Z=79)  
Undoubtedly gold has received the majority of attention in relation to its 
potential as a radiosensitiser. This is due to gold’s presumed 
biocompatibility, supported by its historical use in the treatment of 
rheumatoid arthritis and its superior absorption of X-rays over soft tissue  
(13, 35). Early work by Regulla et al (1998) clearly demonstrated the 
radiosensitising potential of gold. In particular, an enhanced biological 
effect was observed in vitro when monolayers of mouse embryo 
fibroblasts were irradiated in close contact to thin metallic gold foil. 
Analysis of the survival curves of cells irradiated in the absence and 
presence of gold, revealed dose enhancement factors (DEFs) of up to 50  
(36). The dose enhancement property of gold was further illustrated by 
Herold et al. using 3 μm gold microspheres irradiated with various 
kilovoltage energy X-ray beams  (37). DEFs of 1.42 were reported 
following irradiation of rodent cells with 200 kVp X-rays in the presence 
of 1% gold. In addition, the significance of incident photon energy was 
demonstrated when no radiosensitisation was observed using a Cs-137 
source, emitting 662 keV γ-rays. This strongly highlights the importance 
of the differential in mass absorption coefficient between soft tissue and 
high Z materials over the kilovoltage energy range. However, attempts to 
deliver the microspheres to in vivo subcutaneous tumours by intra-
tumoural injection resulted in little radiosensitisation. The lack of effect 
was attributed to the fact that the microspheres were found to 
accumulate at the injection sites and were not homogeneously 
distributed throughout the tumour volume  (37).  
The surge of interest in nanotechnology and specifically nanomedicine 
accelerated the development of gold nanoparticles (GNPs) as novel 
radiosensitising therapeutics. These smaller particles circumvented many 
of the delivery issues associated with larger bulk gold, while apparently 
retaining its attractive biologically inert properties. Initial in vivo proof of 
concept experiments where subcutaneous EMT-6 mammary carcinomas 
were administered with 1.35 mg Au/g, produced no discernable impact 
on tumour growth rates as compared with the untreated control animals, 
highlighting the lack of biological activity. However, when the same dose 
of GNPs were delivered 2 min prior to radiation treatment, potent 
radiosensitisation, cumulating in tumour regression was observed out to 
1 year post treatment  (38). While this experimental setup clearly 
demonstrates the efficacy of GNPs as in vivo radiosensitisers, there are 
fundamental concerns in that the sheer quantity of GNPs administered to 
achieve this therapeutic effect would prove prohibitive on a cost basis if 
scaled for therapeutic purposes.  
Despite these potential issues, numerous groups have performed detailed 
investigations of the effects of multiple variables including particle size, 
shape, surface coating, concentration and photon energy on the 
radiosensitising potential, the key findings of which are summarised in 
Table 1. Given the sheer number of variables presented it is difficult to 
draw direct comparisons between studies, however, taken together the 
results highlight a number of fundamentally important findings which 
require further discussion.  
One such example is the apparent disparity between the radiation 
sensitivity of different tumour cell lines, despite continuity between all 
other variables (5). Although GNP uptake was found to occur in all three 
cell lines investigated, it was greatest in the MDA-MB-231 cells; 
suggesting that both intracellular gold concentration and localisation 
strongly influence the potential radiosensitisation  (39). Also of significant 
interest is the disconnect between the observed experimental data and 
the predicted magnitude of dose enhancement.  Roeske et al. performed 
a comprehensive Monte Carlo modelling study investigating the dose 
enhancing properties of various high Z materials over a range of kV X-ray 
energies, from which the take home message was that a GNP 
concentration of >0.1% by weight (i.e. 1 mg/g tumour) is necessary to 
generate radiosensitisation using low energy x-rays  (40).  However, 
significant radiosensitisation has been reported in vitro using 
considerably lower concentrations of GNPs  (5, 41). Specifically, a dose 
enhancement of 1.05 was theoretically predicted to occur for a GNP 
concentration of 0.05% by mass (i.e. 500 μg/mL) in combination with 160 
kVp X-rays, however, the observed experimental data produced a 
maximal DEF of 1.4 in MDA-MB-231 cells treated with 1.9 nm GNPs, 24 h 
prior to irradiation (5). Rahamen et al. also demonstrated this greater-
than-predicted effect with the same GNP preparation. Used to pre-treat 
bovine aortic endothelial cells at a concentration of 41 μg/mL, a DEF of 
1.24 was achieved, 11% greater that the predicted dose enhancement  
(42). These results suggest that overly simplistic models, which make 
assumptions based purely on physical dose enhancement, homogeneous 
nanoparticle distribution and whole cell systems fail to account for the 
contribution of nanoscale energy deposition and complex biological 
interactions  (10).   
One of the most clinically significant findings in relation to the 
development of GNPs as radiosensitisers was the evidence that 
sensitisation using MV X-rays was achievable. These finding appear to 
contradict the physical similarities between the mass energy absorption 
coefficients of gold and soft tissue using MV radiation sources. Despite 
this numerous groups have reported significant DEFs using clinical 
radiation sources delivering MV X-rays  (5, 43-45). The data presented by 
Chithrani et al clearly demonstrate this effect. Although a maximum 
radiosensitising effect was found for cells irradiated with 105 kVp X-rays 
in the presence of 760 μg/mL GNPs, a DEF of 1.17 ± 0.02 was reported in 
combination with unmodified LINAC-generated 6 MV X-rays  (43). This 
result is in clear disagreement with a theoretically predicted value of 
1.008, again highlighting the complex nature of nanoparticle-induced 
radiosensitisation and the need to consider the shower spectrum (11).  
Pre-clinical evaluation  
Recently, several pre-clinical in vivo models for multiple cancer types have 
demonstrated efficacy in relation to GNP radiosensitisation. Utilising 1.9 
nm GNPs, Hainfeld et al. investigated how radiation dose, beam energy 
and hyperthermia influenced the potential radiosensitising effect of mice 
bearing SCCVII squamous cell carcinoma tumours  (46). Briefly, mice were 
pre-treated using GNPs at a concentration of 1.9 g/kg body weight just 
prior to radiation treatment. Experimental efficacy was determined by 
the increase in tumour doubling time. On average tumours pre-treated 
with GNPs and irradiated with 42 Gy using 68 keV X-rays took 43% longer 
to double in volume compared with radiation only treated mice. In 
addition, an X-ray energy dependency was demonstrated as the same 
approximate dose delivered using 157 keV X-rays yielded a mere 7% 
extension in tumour growth delay in the presence of GNPs. This was 
attributed to the fact that for 68 keV X-rays, almost 100% of the gold-
absorbed photon energy is deposited inside the tumour volume, given the 
range of the ejected photoelectrons and low energy secondary and Auger 
electrons that are subsequently emitted  (46).  The same group recently 
published impressive tumour growth delay data in a model mimicking 
aggressive human glioblastoma cancer. In this instance non-
functionalised 11 nm GNPs were administered by i.v. injection 15 h prior 
to radiation treatment. Interestingly, GNPs did not have the ability to 
cross the normal blood-brain barrier, but efficiently crossed the blood-
tumour barrier to accumulate within the tumour at a 19:1 tumour-to-
normal brain ratio. These glioblastoma tumours proved imminently lethal 
in the absence of any therapeutic intervention, with 0% (n=10) of the 
animals surviving beyond 23 days. Unsurprisingly, irradiation treatment 
extended survival, although all animals had succumbed by day 150 post 
treatment. However, the combination of pre-administration of 4g Au/kg 
prior to radiation resulted in 50% long term (>1 year) survival, markedly 
increasing the therapeutic efficacy of radiation therapy alone  (47)(Figure 
2).      
A new generation of molecularly targeted GNP preparations are being 
developed to avoid over dependence on passive targeting strategies such 
as the EPR effect. This is particularly relevant to nanoparticles with an 
outer gold shell due to the established surface chemistry of GNPs for the 
attachment of targeting agents  (48, 49). One such example is the 
development of a functionalised GNP designed to target the Human 
Epidermal Growth Factor Receptor-2 (HER-2), by conjugating the 
monoclonal antibody trastuzumab to a 30 nm GNP, generating Au-T (Au-
P – a control non targeted 30 nm GNP)  (50).  Using an MDA-MB-361 HER-
2 positive model of breast cancer, the authors demonstrated an in vitro 
dose enhancement factor of 1.6 using 100 kVp X-rays, delivered 24 h after 
GNP administration. Furthermore, treatment of established MDA-MB-
361 sub-cutaneous tumours with Au-T and 11 Gy, translated into a 46% 
reduction of tumour burden over a 120-day time period. This compared 
favourably to radiation treatment alone, which produced an overall 16% 
increase in tumour burden.  The authors of this study attribute the 
mechanism by which Au-T exerts its sensitising effects to Auger electron 
induced double strand break damage (DSB). The in vitro γ-H2AX foci 
formation data supports this conclusion indicating a 1.7 and 3.3 fold 
increase in DSB damage in cells pre-treated with Au-P and Au-T 
respectively  (50)(Figure 3). Perhaps the most interesting finding was the 
additional efficacy conferred by the addition of trastuzumab to the GNP. 
A reasonable assumption would be that conjugation of the antibody 
would enhance systemic targeting ability, however, the Au-T nanoparticle 
preparation also appears to promote cellular uptake following direct 
application. 
Increasingly complex nanoparticle formulations illustrate the potential 
which nanotechnology holds.  The high relative biological effectiveness 
(RBE) produced by α-emitters is particularly attractive in terms of future 
targeted cancer therapeutics. However, the excessive production of 
radioactive daughters following α-particle decay severely restricts their 
therapeutic potential due radiation-induced toxicity to healthy, non-
target tissue  (51).  To circumvent this issue, McLaughlin et al. have 
developed a multi-layered nanoparticle with the α-emitter 225Ac located 
at the core of the structure (52)(Figure 4). The α-emitter was then 
wrapped with a composite material composed of equimolar quantities of 
Lanthanum and Gadolinium orthophosphate {La0.5Gd0.5}(225Ac)PO4, 
utilising the radiation resistant properties of Lanthanum to act as shield 
preventing the release of low energy radioactive daughters such as 221FR. 
This generates a 4 nm central nanoparticle to which four additional layers 
of Gadolinium orthophosphate (GdPO4) are added providing additional 
protection against radioactive decay by-products and conferring the 
magnetic properties of Gadolinium, thereby producing an effective 
contrast agent for systemic MRI scanning. The final layer involves the 
addition of an outer gold shell, permitting functionalisation using 
targeting ligands and conferring the biocompatibility properties 
associated with gold.  The decay process for 225Ac produces 4 α-particles 
with a mean energy of 6.2 MeV, meaning layered encapsulation 
attenuates less than 0.2% of their energy as they exit the centre of the 
nanoparticle. Conversely, 99.99% of the low energy radioactive daughters 
(<100 keV) are effectively retained within the layered nanoparticle 
preventing non-target tissue damage, a key concern of many α-emitting 
therapeutics. In addition, to this the authors also presented convincing 
evidence of effective systemic targeting. Conjugation of the monoclonal 
antibody 201b to the outer gold surface of the nanoparticle enabled 
targeting of the thrombomodilin receptor, which is highly expressed in 
lung endothelium. This was confirmed by whole animal SPECT/CT imaging 
1 h post administration of the nanoparticle, with high accumulations 
localised to the lung in the mAb 201b targeted NP, while the non-targeted 
equivalent nanoparticles accrued preferentially within the liver and 
spleen. Currently, targeted alpha therapy experiments in tumour model 
systems are underway to directly assess the therapeutic efficacy of these 
nanoparticles  (52).  
Gold nanoparticle clinical trials  
Despite the wealth of proof-of-concept and pre-clinical data supporting 
GNPs as effective radiosensitisers, only two GNP based preparations have 
proceeded into clinical trials. CYT-6091 is a novel nanomedicine, which is 
composed of a 27 nm colloidal GNP, surface functionalised with 
thiolyated polyethylene glycol (PEG) and recombinant human tumour 
necrosis factor alpha (rhTNF). TNF as an anti-cancer therapeutic has been 
extensively investigated producing minimal clinical benefit with dose 
limiting side effects including hepatotoxicity, malaise and hypotension 
(53-56). This was thought to be, in part, due to the inability to adequately 
target the drug to the site of disease. In the development and preclinical 
evaluation of CYT-6091, the inclusion of PEG along with rhTNF restricted 
rapid uptake by the reticuloendiothelial system as well as limiting toxicity 
associated with rhTNF (57). Development of CTY-6091 progressed to a 
phase I dose escalation study in advanced stage cancer patients. Doses 
ranging from 50 μg/m-2 to 600 μg/m-2 were administered with no major 
dose limiting toxicity reported, while the maximum tolerated dose was 
not obtained. Interestingly, the dose of GNP bound rhTNF was three times 
higher than the maximum tolerated dose of free rhTNF. Tumour specific 
targeting of the rhTNF-GNP was passively achieved by the EPR effect. This 
was confirmed by transmission electron microscopy analysis of post-
treatment core biopsies, which indicated the presence of GNPs 
specifically within the tumour tissue while remaining undetectable in the 
healthy tissue  (58).  Although, this trial did not investigate the potential 
efficacy of a combined radiotherapy treatment plan, the target site 
accumulation of rhTNF resulted in one partial response and three patients 
achieving stable disease states  (59).   
An ongoing pilot study due for completion in December 2013, is 
investigating the potential for adverse side effects and any therapeutic 
benefit conferred to targeted tumours following a course of AuroLase® 
therapy. This is a photothermal therapy designed to confer anti-tumour 
efficacy by the conversion of near infrared laser energy to heat using small 
gold coated nanoparticles called Auroshells®. Auroshells combine the 
biologically inert properties of GNPs with a non-conducting, dielectric 
silica core designed to act as an exogenous absorber of near infrared laser 
energy, thus promoting tumour ablation by hyperthermia. As before, the 
GNPs are designed to passively accumulate within the tumour by the EPR 
effect. Extensive preclinical evaluations of Auroshells reported that the 
particles were well tolerated when injected i.v. with no toxicities or 
bioincompatibilities observed  (60). The study aims to deliver a single dose 
of Auroshells followed by one or more interstitial illuminations with an 
808 nm laser, with tumour nanoparticle uptake estimated by neutron-
activated analysis from post-treatment biopsies  (61).  
Conclusions  
The sheer diversity and complexity of nanoparticle preparations that have 
been developed hold significant potential for the treatment of a plethora 
of disease states including cancer. However, there remain many 
uncertainties, not least those based around the predictions that high Z 
radiosensitisation is solely attributed to the differential mass absorption 
coefficient of high Z materials and soft tissue. This was born out through 
numerous reports of significant disparities between the biological 
responses and the predicated outcome based on physical interactions. 
Moreover, the assumption that nanomaterials will exhibit the same 
degree of biological and chemical inactivity to bulk material appears to 
have been overly simplistic, with contradictory reports of toxicity for 
presumed inert materials such as gold in the nanoscale range. Due to the 
extensive variability of base material, size, charge, shape, surface coating 
and functionalisation, relative comparisons of radiosensitisation 
capabilities are impossible, therefore requiring each nanoparticle 
preparation to be extensively evaluated on its own merit. This exhaustive 
process will inevitably delay progression towards the clinic. This is delay 
is best illustrated by the disparity in complexity of the advanced particles 
investigated in pre-clinical models and the relative simplicity of the 
targeting and therapeutic approaches for nanoparticle preparations 
which have entered clinical trials. Furthermore, there is a significant lack 
of pre-clinical in vivo data demonstrating therapeutic efficacy using 
clinically relevant MV photon energies, despite numerous in vitro models 
suggesting radiosensitising efficacy using high Z materials.  
There is little doubt that nanotechnology has a huge potential to 
significantly augment the therapeutic benefit of current treatment 
modalities such as chemo- and radiotherapy. However, without rigorous 
quality control to limit internal production variability and detailed 
systematic evaluations of efficacy, which currently appear to be lacking, 
the true potential of radiosensitising nanoparticles may not be realised 
for some time.   
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Figure Legends  
Figure 1. Enhanced contract properties conferred by GNP accumulation 
within the brain of a 9LGS-bearing rat before and 5, 20, and 45 min after 
intravenous injection of GBNs. 
Figure 2. Kaplan–Meier survival curves of mice bearing Tu-2449 highly 
malignant tumours indicative of human gliomas. Only animals receiving 
the combination therapy of GNPs plus radiation treatment survived in 
excess of 1-year post treatment.   
Figure 3. Induction of DSB damage in MDA-MB-361 cells pre-treated with 
trastuzumab functionalised GNPs. DSB damage was quantified by γ-H2AX 
foci formation. The presence of the HER-2 monoclonal antibody 
significantly increased the DNA damage profiles following radiation 
treatment.  
Figure 4. A schematic representation of a gold-coated lanthanide 
phosphate nanoparticle. Located in the center of the nanoparticle is the 
{La0.5Gd0.5}PO4 α-emitter. This is surrounded by four GdPO4 layers that 
retain radioactive decay products, and a gold shell, which increases 
biocompatibility and provides a surface for functionalisation. 
 
Table 1. A summary of the findings of in vitro studies investigating the 
effect of GNPs in combination with ionising radiation. Predicted dose 
enhancement factors were calculated based on the mass fraction of GNP 
used, beam energy and the mass attenuation coefficient.     
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